Genomate Health

07/18/2025

This simple moment - applying sunscreen before heading outside - is more than just routine.
It’s protection.
It’s prevention.
It’s care.

Most skin cancers are caused by UV exposure, and they’re often preventable with small, consistent actions like wearing sunscreen, covering up, and seeking shade.

At Genomate Health, we focus on supporting patients through some of the most complex cancer journeys, but we know that prevention is the first step in better cancer care.

This July, for , we’re honoring the small choices that protect the people we love.

07/11/2025

A cancer diagnosis changes everything, not just for you, but for everyone who loves you. Suddenly, your world is filled with questions you never imagined you’d have to ask.

One thing that shouldn’t be uncertain? Whether you’re getting the best possible treatment plan for your cancer. That’s what you, your family, and your oncologist all want; and it’s what drives us at Genomate Health every single day.

Your oncologist works tirelessly to choose the right approach, often under enormous pressure. Our role is to help them see the full molecular picture, so they have the clearest information to guide every decision, no matter how complex your cancer might be.

For you, it means knowing you’re not settling for generic options. It means understanding your choices and feeling confident that your care is as personal and precise as possible.

For your doctor, it means having an extra layer of insight, highlighting what matters most and what might otherwise be missed.

And for us, it means standing behind you both, bringing clarity to complexity so you can focus on what matters most: your life, your family, your future.

Ask your care team for a Genomate® Report.

07/05/2025

Behind every patient helped, every treatment guided, and every data point made clear is a dedicated team of researchers, scientists, engineers, and innovators making it possible.

Behind every Genomate Report is not just data, but the collective expertise, passion, and commitment of people who believe patients deserve better options and clearer answers. To our team - and to researchers everywhere - thank you for turning complexity into clarity, for asking the hard questions, and for never settling for “good enough.”

Here’s to the people behind the progress.

07/03/2025

Pain, swelling, or a lump that doesn’t go away?
Do not ignore it. Persistent pain, especially in young people and athletes, should never be brushed off as “just an injury” if it lingers or worsens.

Sarcomas are rare but aggressive cancers that can develop in bones and soft tissues. They’re often overlooked because early symptoms can seem harmless.

At Genomate Health, we believe early detection and precision oncology can make all the difference for rare and complex cancers like sarcomas. Our computational reasoning tools help oncologists uncover personalized treatment options for patients who need more than standard care.

This month, help us spread the word.
Listen to your body.
Speak up about unexplained pain.
Advocate for the right tests.
Early action saves lives.

06/25/2025

How does Genomate® help oncologists make smarter, more confident treatment decisions?

Our latest study, published in Nature’s npj Precision Oncology, shows how Genomate doesn’t just analyze molecular data. It translates it into action.

Here’s what makes Genomate different:
🔍 We alert oncologists to the most important genetic alteration, so they know where to focus first
⚠️ We flag resistance mechanisms, helping avoid therapies likely to fail
🎯 We optimize for maximum clinical benefit, going beyond matching drugs to mutations, to deliver the most meaningful care options

In other words: we bring clarity to complexity.

See the results: https://www.genomate.health/publication/genomate-real-world-performance-analysis-in-lung-cancer
Read the full publication in Nature: https://www.nature.com/articles/s41698-025-00943-4

Anna Dirner, Dóra Kormos, Dóra Lakatos PhD, Márton Bolyácz, Mária Kocsis-Steinbach, Kalmar Gabor, Dóra Tihanyi, Akos Takacs, Ákos Boldizsár PhD, Viktor Kardos, Réka Szalkai-Dénes, Barbara Vodicska PhD, Edit Varkondi, Julia Deri, Gábor Pajkos MD, CSc, Dora Mathiasz, Istvan Valyi-Nagy, Richard SCHWAB M.D., Maud Kamal, PhD, Christian Rolfo, MD, PhD, MBA,Dr.hc, Arkadiusz Dudek, Christophe Le Tourneau, Robert Doczi, PhD, Urban laszlo, Istvan Petak MD, PhD

06/20/2025

From routine checkups to life-saving screenings, Men’s Health Day is a reminder to take proactive steps toward better well-being, especially when it comes to cancer.

Men face a higher risk for several cancers, including prostate, bladder, colorectal, or head and neck cancers, many of which can be treated more effectively with early detection and personalized care.

At Genomate Health, we support oncologists with computational reasoning tools that decode complex molecular data to identify tailored treatment strategies for every patient, including those facing aggressive or treatment-resistant cancers.

This month, let’s challenge the silence around men’s health. Encourage checkups. Share knowledge. And advocate for care that’s as individual as the patient.

06/16/2025

Cancer doesn’t impact all communities equally.

Black families in the U.S. face persistent disparities in cancer diagnosis, treatment access, and outcomes; yet these inequities are too often overlooked.

At Genomate Health, we believe that precision oncology must include equity by design. That means ensuring all patients (regardless of background) have access to advanced molecular profiling and data-driven treatment strategies that reflect their unique biology.

This week is a call to action:
↘ Talk about your family’s cancer history
↘ Advocate for early screening and better care
↘ Champion access to innovation for all

Because awareness is powerful, but action saves lives.

06/14/2025

Today we recognize the donors whose simple act of giving saves millions of lives every year. Blood transfusions are critical in cancer care, from supporting patients during chemotherapy to managing complications during surgery.

Let’s continue to raise awareness, donate when we can, and support the systems that make care possible: https://www.who.int/campaigns/world-blood-donor-day/2025

To everyone who rolls up their sleeve to give others another chance: THANK YOU!

06/12/2025

What if every lung cancer patient could get a treatment plan built just for them, using the full picture of their tumor, not just one mutation?

That’s the question behind Genomate®. And now, we have real-world data to show it works.

We’re proud to share our latest real-world performance analysis, published in Nature Magazine's npj Precision Oncology, showing that Genomate® helps oncologists make more effective treatment decisions for lung cancer patients.

In a retrospective analysis of 111 lung cancer cases:
✅ 4x longer progression-free survival with Genomate’s top-ranked therapies
✅ 33% 5-year survival rate, using approved, available drugs
✅ Over 50% of patients were matched to high-scoring treatments

This isn’t theoretical. It’s precision oncology, in practice, delivered with clarity and equity.

Here's how we’re making it real: https://www.genomate.health/publication/genomate-real-world-performance-analysis-in-lung-cancer

Anna Dirner, Dóra Kormos, Dóra Lakatos, Márton Bolyácz, Mária Kocsis-Steinbach, Kalmar Gabor, Dóra Tihanyi, Akos Takacs, Ákos Boldizsár PhD, Viktor Kardos, Réka Szalkai-Dénes, Barbara Vodicska PhD, Edit Varkondi, Julia Deri, Gábor Pajkos MD, CSc, Dora Mathiasz, Istvan Valyi-Nagy, Richard SCHWAB M.D., Maud Kamal, PhD, Christian Rolfo, MD, PhD, MBA,Dr.hc, Arkadiusz Dudek, Christophe Le Tourneau, Robert Doczi, PhD, Urban laszlo, Istvan Petak MD, PhD

Lung cancer remains the leading cause of cancer-related deaths globally, accounting for approximately 1.8 million deaths each year. While molecular testing has become more common, treatment decisions are still often based on single biomarkers, which fail to reflect the complexity of most tumor genom...

06/11/2025

June is , a time to talk openly about the diseases that affect men most. Lung cancer is one of them.

In 2025, over 226,650 people in the U.S. will be diagnosed with lung cancer, and men are disproportionately affected. Despite progress in early detection and treatment, far too many still face late diagnoses, limited options, or mismatched therapies.

This month, we remember that behind every case is a name, a family, a story.
And with the right tools, we can change how those stories unfold:
↘ Men deserve personalized, effective cancer care
↘ Not just what’s available, but what’s best for their unique molecular profile
↘ And not just for the lucky few, for everyone

At Genomate Health, we believe that everyone diagnosed with cancer deserves the best possible therapy, guided by science, not chance. Here’s how we’re working toward that future: https://www.nature.com/articles/s41698-025-00943-4

06/01/2025

Today, we celebrate the strength, resilience, and stories of millions of cancer survivors around the world.

At Genomate Health, we’re honored to support the clinicians, researchers, and patients who make survivorship possible, especially those navigating complex diagnoses that require more than standard care.

Every survivor’s journey is unique. That’s why we’re committed to advancing precision oncology through computational reasoning, helping care teams deliver personalized treatment strategies that give patients not just hope, but options.

To all those living with, through, and beyond cancer: We see you. We honor you. We’re with you.

05/30/2025

We’re proud to announce the publication of our team’s latest research in Nature Magazine’s npj Precision Oncology, offering real-world evidence on the power of Digital Drug Assignment (DDA) to transform treatment journeys for lung cancer patients.

This study followed real-world patients who received precision oncology decision support powered by Genomate’s computational reasoning engine. The findings speak for themselves:

✅ Molecularly targeted agents (MTAs) with high Digital Drug Assignment (DDA) scores delivered a median progression-free survival (mPFS) of 32 months versus 8 months of other treatments;

✅ Median overall survival (mOS) was 67 months for patients treated with at least one high-score DDA MTA vs. 15 months for those who didn’t. Moreover, the 5-year survival rate was 33% for patients treated with at least one high-score DDA MTA, compared to 6% for others;

✅ Overall Response Rates (ORR) with high-score DDA MTAs reached 58%, more than double that of other treatments.

At Genomate Health, we are building the future of oncology by applying computational reasoning to real-world complexity, delivering clarity, confidence, and improved survival outcomes. Because the right treatment, at the right time, for the right patient isn’t just possible — it’s essential.

Read the full publication: https://www.nature.com/articles/s41698-025-00943-4

Anna Dirner , Dóra Szaszkó-Kormos, Dóra Lakatos, Márton Bolyácz, Mária Kocsis-Steinbach, Kalmar Gabor, Dóra Tihanyi, Akos Takacs, Ákos Boldizsár PhD, Viktor Kardos, Réka Szalkai-Dénes, Barbara Vodicska PhD, Edit Varkondi, Julia Deri, Gábor Pajkos MD, CSc, Dora Mathiasz, Istvan Valyi-Nagy, .richard M.D., Maud Kamal, PhD, Christian Rolfo, MD, PhD, MBA,Dr.hc, Arkadiusz Dudek, Christophe Le Tourneau, Robert Doczi, PhD, Urban Laszlo & MD, PhD